![CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz](https://biobuzz.io/wp-content/uploads/2022/01/CASI_HR-1024x426.png)
CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz
![CASI Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CASI) | Seeking Alpha CASI Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CASI) | Seeking Alpha](https://static2.seekingalpha.com/uploads/sa_presentations/418/83418/slides/1.jpg?0)
CASI Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CASI) | Seeking Alpha
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd -December 08, 2023 at 04:06 pm EST | MarketScreener
![Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research](https://pricetargetresearch.com/wp-content/uploads/2022/08/out_mm25510.jpg)